NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?

Despite its growing prevalence, there are currently no treatment options for patients with nonalcoholic steatohepatitis (NASH). Now, Novartis and Pfizer and are teaming up in an attempt to change that with a new joint development program for the chronic liver disease.